COMMUNIQUÉS West-GlobeNewswire

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
31/10/2025
Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose level Positive data from ATH434-202 open-label trial demonstrates similar treatment effect in advanced MSA as observed in [...]
Vireo Growth Inc. to Release Third Quarter 2025 Results on November 12, 2025
31/10/2025
MINNEAPOLIS, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its third fiscal quarter ended [...]
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
31/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including three Late Breaking Science presentations related to MAPLE-HCM [...]
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
31/10/2025
Conference Call to be Held Monday, November 3, 2025, at 8:30 am ET NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November [...]
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
31/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct [...]
Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
31/10/2025
Vancouver, Canada, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
31/10/2025
COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its [...]
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
31/10/2025
NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets [...]
Alps Announces Closing of Business Combination with Globalink Investment Inc.
31/10/2025
Alps ordinary shares to list on the Nasdaq under the symbol “ALPS” on October 31, 2025 KUALA LUMPUR, Malaysia and NEWARK, Del., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Alps Group Inc (the “ Company ” or “ Alps Group ”), the [...]
Certara to Participate in Upcoming Investor Conferences
31/10/2025
RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025
31/10/2025
Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine [...]
Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ® 25 and 50 mg
31/10/2025
Second API manufacturing facility added to ensure supply for patients with insomnia in Japan and for future demand across the Asia-Pacific region Expected to improve profitability through manufacturing cost reductions [...]
Vistin Pharma ASA: Third quarter and YTD 2025 financial results
31/10/2025
Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31 st of October 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025. Revenue in the third [...]
Corbus Pharmaceuticals Announces Pricing of Public Offering
31/10/2025
NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public [...]
DXS International plc ((AQSE: DXSP) - Final Results
31/10/2025
DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS for the year ended 30 April 2025 The Board of DXS International plc (“the Company”), the AQSE Growth Market quoted healthcare information and digital clinical decision [...]
NANOBIOTIX annonce un accord stratégique avec HealthCare Royalty pour un montant maximum de 71 millions de dollars et prolonge ainsi son horizon de trésorerie pour une croissance durable
31/10/2025
Les 71 millions de dollars américains permettraient à Nanobiotix d’étendre son horizon de trésorerie jusqu’au début de l’année 2028. Cette opération donne à Nanobiotix la capacité financière de se développer au-delà des [...]
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
31/10/2025
$71 million in funding would extend Nanobiotix cash visibility into early 2028 Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancer Financing establishes financial [...]
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2025
31/10/2025
Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat’ at the Jefferies [...]
Unprecedented Clinical data from the Landmark BOOSTB4 Trial to be presented at the 15th International Conference on Osteogenesis Imperfecta in Hong Kong
31/10/2025
COPENHAGEN, Denmark, Oct. 31, 2025 (GLOBE NEWSWIRE) -- BOOST Pharma, a clinical-stage cell biotech company focused on rare skeletal pediatric diseases, is proud to announce that new long-term data from the first-in- [...]

Pages